Spark Therapeutics (NASDAQ:ONCE) and TrovaGene (NASDAQ:TROV) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Spark Therapeutics and TrovaGene, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Spark Therapeutics 0 11 0 0 2.00
TrovaGene 0 0 2 0 3.00

Spark Therapeutics presently has a consensus price target of $106.00, suggesting a potential downside of 6.67%. TrovaGene has a consensus price target of $14.50, suggesting a potential upside of 616.40%. Given TrovaGene’s stronger consensus rating and higher possible upside, analysts plainly believe TrovaGene is more favorable than Spark Therapeutics.

Insider & Institutional Ownership

88.4% of Spark Therapeutics shares are held by institutional investors. Comparatively, 9.8% of TrovaGene shares are held by institutional investors. 6.0% of Spark Therapeutics shares are held by insiders. Comparatively, 1.2% of TrovaGene shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.


This table compares Spark Therapeutics and TrovaGene’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Spark Therapeutics -358.41% -59.10% -33.13%
TrovaGene -3,797.67% -185.18% -119.86%

Volatility and Risk

Spark Therapeutics has a beta of 2.05, suggesting that its share price is 105% more volatile than the S&P 500. Comparatively, TrovaGene has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500.

Earnings and Valuation

This table compares Spark Therapeutics and TrovaGene’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Spark Therapeutics $64.72 million 67.59 -$78.82 million ($2.11) -53.82
TrovaGene $380,000.00 41.23 -$16.46 million ($8.26) -0.25

TrovaGene has lower revenue, but higher earnings than Spark Therapeutics. Spark Therapeutics is trading at a lower price-to-earnings ratio than TrovaGene, indicating that it is currently the more affordable of the two stocks.


Spark Therapeutics beats TrovaGene on 9 of the 14 factors compared between the two stocks.

About Spark Therapeutics

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells. The company's gene therapy product candidates comprise SPK-8011 and SPK-8016 for hemophilia; SPK-7001 for choroideremia; and SPK-9001 for hemophilia B. It is also developing other liver-directed gene therapies, including SPK-3006 for Pompe disease; and neurodegenerative disease product candidates to address Huntington's disease and others, as well as TPP1 deficiency, which is a form of Batten disease. The company's preclinical programs targets inherited retinal diseases, including Stargardt's disease. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. It also has licensing and commercialization agreement with Novartis to develop and commercialize voretigene neparvovec outside the United States. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania.

About TrovaGene

Trovagene, Inc., a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor. The PCM-075 is in Phase Ib/II clinical trial in acute myeloid leukemia (AML) and has completed a Phase I clinical trial in advanced solid tumors. The PCM-075 is also in preclinical studies with approximately 10 chemotherapeutic and target agents used in hematologic and solid tumor cancers, including Zytiga (abiraterone acetate); Beleodaq (belinostat); Quizartinib (AC220), a development stage FLT3 inhibitor; and Velcade (bortezomib) in AML, metastatic castration-resistant prostate cancer and other hematologic and solid tumor cancers. Trovagene, Inc. primarily serves pharmaceutical companies and third party laboratories. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene, Inc. in January 2010. Trovagene, Inc. was founded in 1999 and is headquartered in San Diego, California.

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with's FREE daily email newsletter.